Dan Michels began his FDA career as a Field Investigator (then Inspector) in the San Francisco District in 1963. He transferred in 1969 to the Bureau of Medicine, which was shortly thereafter reorganized into the Bureau of Drugs. He served as a program analyst, Director of the Division of Planning and Evaluation, Deputy Director of the Division of Scientific Investigations, and Acting Deputy Associate Director for New Drug Evaluation (Scientific). From 1982 to 1992 he served as Director of the CDER Office of Compliance. His last position at FDA was Director of the Office of Enforcement in the Office of Regulatory Affairs. He retired from FDA in 2000 and joined KMI, a division of PAREXEL International, as a senior compliance consultant. Since 2004 he has worked part-time as an independent consultant. In addition to joining FDAAA early in its inception, he is also a member of FDLI and RAPS, and is a lifetime member of the Senior Executives Association.